@article{d4448e968d0443e987b40b40538acc25,
title = "Autologous transplantation for diffuse aggressive Non-Hodgkin lymphoma in first relapse or second remission",
abstract = "We evaluated the results of high-dose chemotherapy and autologous hematopoietic stem cell transplantation in patients with diffuse aggressive non-Hodgkin lymphoma (NHL) in first relapse (Rel 1) or second complete remission (CR 2). Data were evaluated from the Autologous Blood and Marrow Transplant Registry on 429 patients with diffuse aggressive NHL who underwent transplantation in Rel 1 or CR 2. Transplantations were performed between 1989 and 1996 and were reported to the Autologous Blood and Marrow Transplant Registry by 93 centers in North and South America. The probability of 3-year survival was 44% (95% confidence interval [CI], 33%-55%). The probability at 3 years of progression-free survival was 31% (95% CI, 27%-36%). Patients who underwent transplantation in CR 2 had a 3-year probability of progression-free survival of 38% (95% CI, 30%-46%) compared with 28% (95% CI, 22%-33%) for those who were not in remission at the time of transplantation (P<.001). In multivariate analysis, chemotherapy resistance, increased lactic dehydrogenase at diagnosis, an interval of <12 months from diagnosis to relapse, age ≥40 years, and use of myeloid growth factors to accelerate posttransplantation bone marrow recovery were adverse predictors of survival. High-dose chemotherapy and autologous hematopoietic stem cell transplantation for patients with diffuse aggressive NHL in CR 2 or Rel 1 resulted in better outcome for patients with chemotherapy-sensitive disease, longer relapse-free intervals, and age <40 years. Exposure to myeloid growth factors to accelerate recovery for recipients of bone marrow grafts may increase the risk of disease progression or death.",
keywords = "Hematopoietic stem cell transplantation, High-dose chemotherapy, Non-Hodgkin lymphoma",
author = "Vose, {Julie M.} and Rizzo, {Douglas J.} and Jing Tao-Wu and Armitage, {James O.} and Asad Bashey and Burns, {Linda J.} and Christiansen, {Neal Paul} and Freytes, {Cesar O.} and Gale, {Robert Peter} and John Gibson and Giralt, {Sergio A.} and Herzig, {Roger H.} and Lemaistre, {Charles F.} and McCarthy, {Philip L.} and Nimer, {Stephen D.} and Petersen, {Finn B.} and Schenkein, {David P.} and Wiernik, {Peter H.} and Wiley, {Joseph M.} and Loberiza, {Fausto R.} and Lazarus, {Hillard M.} and {van Biesen}, Koen and Horowitz, {Mary M.}",
note = "Funding Information: Supported by Public Health Service grant no. U24-CA76518 from the National Cancer Institute, the National Institute of Allergy and Infectious Diseases, and the National Heart, Lung and Blood Institute; and grants from Allianz Life/Life Trac; the American Cancer Society; the American Red Cross; the American Society of Clinical Oncology; Amgen, Inc.; Anonymous; Aventis Pharmaceuticals; Baxter Healthcare Corp.; Baxter Oncology; Berlex Oncology; Blue Cross and Blue Shield Association; the Lynde and Harry Bradley Foundation; Bristol Myers Squibb Oncology; Cedarlane Laboratories, Ltd.; Cell Pathways; CelMed Biosciences; Centocor, Inc.; Cubist Pharmaceuticals; Darwin Medical Communications, Ltd.; Dynal Biotech ASA; Edwards Lifesciences RMI; Endo Pharmaceuticals, Inc.; Enzon Pharmaceuticals, Inc.; Excess, Inc.; Fujisawa Healthcare, Inc.; Gambro BCT, Inc.; GlaxoSmithKline, Inc.; Human Genome Sciences; ICN Pharmaceuticals, Inc.; ILEX Oncology; the Kettering Family Foundation; Kirin Brewery Company; Ligand Pharmaceuticals, Inc.; Eli Lilly and Company; Nada and Herbert P. Mahler Charities; Merck & Company; Millennium Pharmaceuticals; Miller Pharmacal Group; Milliman USA, Inc.; Miltenyi Biotec; Irving I. Moskowitz Foundation; National Marrow Donor Program; NeoRx; Novartis Pharmaceuticals, Inc.; Novo Nordisk Pharmaceuticals; Orphan Medical, Inc.; Ortho Biotech, Inc.; Osiris Therapeutics, Inc.; PacifiCare Health Systems; Pall Medical; Pfizer U.S. Pharmaceuticals; Pharmacia Corporation; Pharmametrics; Pharmion Corp.; Protein Design Labs; Roche Laboratories; SangStat Medical; Schering AG; StemCyte, Inc.; StemCell Technologies, Inc.; Stemco Biomedical; StemSoft Software, Inc.; SuperGen, Inc.; Sysmex; THERAKOS, a Johnson & Johnson Co.; Unicare Life & Health Insurance; University of Colorado Cord Blood Bank; ViaCell, Inc.; ViaCor Biotechnologies; WB Saunders Mosby Churchill; and Zymogenetics, Inc. The contents of this article are solely the responsibility of the authors and do not represent the official views of the National Cancer Institute.",
year = "2004",
month = feb,
doi = "10.1016/j.bbmt.2003.09.015",
language = "English (US)",
volume = "10",
pages = "116--127",
journal = "Biology of Blood and Marrow Transplantation",
issn = "1083-8791",
publisher = "Elsevier Inc.",
number = "2",
}